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Brain endotheliumnique among endothelial cells in that they express apical junctional complexes,
including tight junctions, which quite resemble epithelial tight junctions both structurally and functionally.
They form the blood-brain-barrier (BBB) which strictly controls the exchanges between the blood and the
brain compartments by limiting passive diffusion of blood-borne solutes while actively transporting
nutrients to the brain. Accumulating experimental and clinical evidence indicate that BBB dysfunctions are
associated with a number of serious CNS diseases with important social impacts, such as multiple sclerosis,
stroke, brain tumors, epilepsy or Alzheimer's disease. This review will focus on the implication of brain
endothelial tight junctions in BBB architecture and physiology, will discuss the consequences of BBB
dysfunction in these CNS diseases and will present some therapeutic strategies for drug delivery to the brain
across the BBB.
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Apical junctional complexes, notably tight junctions, are present in
physiological barriers constituted by a variety of epithelia and in brain
endothelium forming the blood-brain-barrier (BBB) which controls
cerebral homeostasis and provides the central nervous system (CNS)
with a unique protection against the toxicity of many xenobiotics and
pathogens. Conversely, BBB dysfunction has been recently proposed to
be involved in the pathophysiology of a variety of neurological
diseases (inﬂammatory, infectious, neoplasic and neurodegenerative
diseases). This review aims at presenting the most recent knowledge
of BBB architecture and function and will present novel therapeutic
approaches designed to address these neurological diseases on the
basis of this knowledge.
2. Blood-brain barrier in health
2.1. General description
2.1.1. Localization
The BBB is localized at the interface between the blood and the
cerebral tissue [1,2], formed by the endothelial cells (ECs) of cerebral
blood vessels which display a unique phenotype characterized by the
presence of intercellular tight junctions and the polarized expression
of numerous transport systems. Another blood-brain interface is
localized at the choroid plexus epithelium which controls the
exchanges between the blood and the cerebro-spinal-ﬂuid (so-called
the blood-CSF barrier): these specialized epithelial cells also express
tight junctions and a number of transporters, but will not be described
below for space constraints (for reviews, see [3]).
It is worthmentioning at this point that some restricted brain areas
encompassing circumventricular organs (area postrema and median
eminence, neuro-hypophysis, pineal gland, sub-fornical organ and
lamina terminalis) do not present any blood-CNS barrier andFig. 1. The neurovascular unit. A. Electron microscopy (TEM) of rat brain section showing a
lamina, pericytes embedded in basal lamina, astrocytes end-feet and in vicinity some neuron
vascular tree: endothelial cells (green) are surrounding with astrocytes (red), which are visuconstitute specialized sites of physiological cross-talks between the
brain and the periphery (for example regarding food intake or control
of body temperature) [4]; however, they are very limited in size and
will not be described in this review (see [5]).
2.1.2. The neurovascular unit
In close proximity to brain ECs, as shown in Fig. 1, pericytes, glial
cells (especially astrocytes), neurons, together with the basal lamina
(also called lamina basalis) ensheathing cerebral blood vessels, are
indirectly involved in the establishment and maintenance of the BBB:
these various cell types and basal lamina collectively constitute the
‘neurovascular unit’ (NVU), a concept recently proposed to highlight
the functional interactions which control BBB integrity.
2.1.2.1. Endothelial cells. Brain ECs differ signiﬁcantly from non-brain
ECs by (i) the absence of fenestration correlating with the presence of
intercellular tight junctions (TJs), (ii) the low level of non speciﬁc
transcytosis (pinocytosis) and paracellular diffusion of hydrophilic
compounds, (iii) a high number of mitochondria, associated with a
strong metabolic activity and (iv) the polarized expression of
membrane receptors and transporters which are responsible for the
active transport of blood-borne nutrients to the brain or the efﬂux of
potentially toxic compounds from the cerebral to the vascular
compartment [6,7]. In brief, the hallmark of brain endothelium in
mammals is its highly restricted and controlled permeability to
plasmatic compounds and ions, reﬂected by a very high trans-
endothelial electrical resistance [7,8].
2.1.2.2. Basal lamina. The basal lamina of the cerebral endothelium is
constituted by 3 apposed layers, one produced by ECs and containing
laminin-4 and -5, one being astrocyte-derived, containing laminin-1
and -2 and the collagen IV-containingmiddle one, contributed by both
cell types [9]. All three layers are also made of various types of
collagen, glycoproteins and proteoglycans [2,10]. Although itsneurovascular unit. This complex includes microvessel endothelial cells, based on basal
s. B. Confocal microscopy 3D-reconstruction of rat brain section showing part of cerebral
alized with von-Willebrand factor and glial ﬁbrillary acidic protein staining respectively.
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lamina must now be considered as a key component of the NVU [11].
Multiple basal lamina proteins, matrix metalloproteases (MMPs) and
their inhibitors, the Tissue Inhibitor of Metalloproteases (TIMPs), are
involved in the dynamic regulation of the BBB in physiological as well
as inﬂammatory conditions [12].
2.1.2.3. Glial cells, astrocytes. Whereas the role of astrocytes in the
induction and maintenance of BBB integrity has been well documen-
ted for more than two decades [13], the molecular mechanism
mediating their action still remains unclear. Indeed, a number of
astrocyte-released and more generally glial-released factors have
been suggested to contribute to BBB integrity, including glial-derived
neurotrophic factor (GDNF), angiopoietin-1 [14,15] and more recently
angiotensin II [16].
2.1.2.4. Pericytes. Pericytes are present along brain and non-brain
microvessels, within the basal lamina surrounding ECs; interestingly,
brain microvessels are notably rich in pericytes and the pericytes/ECs
ratio has been correlated with the barrier capacity of the endothelium.
Pericytes are actively involved in maintenance of the integrity of the
vessel [17], vasoregulation [18] and restricted BBB permeability.
2.1.2.5. Neurons. Brain endothelium, perivascular astrocytes and
pericytes are in close contact with neuronal projections, allowing
neuronal mediators to affect cerebral blood ﬂow and vessel dynamics.
However, the precise physiological or pathophysiological conse-
quences of neuronal input onto the BBB still remain largely unknown.
2.1.3. In vitro BBB models
In line with the understanding of the aforementioned cell–cell
interactions taking place at the BBB, most in vitro BBB models
proposed so far are based on co-cultures of brain ECs and astrocytes
(or glial cells) [19] in two-chamber cell culture systems (Fig. 2A). InFig. 2.Modeling the blood-brain-barrier and neurovascular unit in vitro. Static BBB models (
Boyden chambers. In order tomodel the NVU, various other cell types (glial cells, pericytes or
three-dimensional ﬂow BBB models (B) provide an interesting model to study brain EC prop
differentiation of cultured brain ECs to a BBB phenotype.particular, whereas bovine brain endothelial cells alone only partly
recapitulate BBB properties, a co-culture systemwith rat glial cells has
been extensively validated as a reference BBB model [20]. Because
these cells express TJs and a number of membrane transporters, they
constitute a valuable alternative or complement to the epithelial cell
lines Caco-2 and MDCK, currently used for drug screening by
pharmaceutical industries because of their very high permeability
restriction [21]. Alternative BBB models are also available, using pig,
mouse, rat or human brain ECs [15,22–28]. In addition, stable
immortalized rat EC lines were produced and validated as in vitro
models of brain endothelium: ﬁrst the RBE4 cell line [29–31], followed
by a number of other cell lines [32–35] have been widely used for
biochemical, immunological and toxicological studies. More recently,
we produced the human hCMEC/D3 brain EC line which retains most
of the morphological and functional characteristics of brain endothe-
lial cells (i.e. expression of TJs and the polarized expression of multiple
active transporters, receptors and adhesion molecules), even without
co-culture with glial cells, thus appearing as a unique in vitromodel of
the human BBB [36–38]. Recently, three dimensional ﬂow conditions
(Fig. 2B) [39] were able to further decrease signiﬁcantly drug
permeability [40]. All together, these in vitro BBB models will help
screening new drugs as well as unraveling the molecular mechanisms
of BBB control in physiological conditions and BBB dysfunctions in
various CNS diseases.
2.2. Intercellular junctions
Tight junctions between brain endothelial cells are structurally
quite similar to epithelial TJs (this issue): they are constituted by three
major transmembrane proteins (or protein families), occludin,
claudins and Junction Associated Molecules (JAMs), and several
cytoplasmic proteins including Zonula Occludens (ZO) -1, ZO-2, ZO-
3, which interact with these transmembrane proteins in multi-protein
complexes linked to the actin cytoskeleton (Fig. 3) [2]. However, EC-A) use brain ECs (1), primary brain ECs or EC lines, grown in the upper compartment of
neurons) can be co-cultured in the lower compartment (2). Recently described dynamic
erties under ﬂow conditions, based on observations that pulsatile ﬂow induces further
Fig. 3. Tight junctions on the blood-brain-barrier. Left: Electronmicroscopy of rat brain section showing a tight junction (TJ) between two cerebral endothelial cells. Right: Schematic
view of cerebral TJ. Cerebral endothelial cells have close intercellular contacts due to the presence of tight junctions (TJs) constituted by transmembrane proteins: occludin, claudins
(claudin-3 and -5) associated with actin cytoskeleton via cytosolic proteins, such as the ZO family. Peripherally to TJs are localized JAMs and proteins of Adherens Junctions, such as
VE-cadherin which is also associated with actin cytoskeleton via catenins.
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such as cingulin, AF-6 and 7H6 [41], whereas some epithelial TJ
proteins have not been detected so far at the BBB (like the CRUMBS/
PALS-1/PAT-J and PAR-3/PAR-6/aPKC complexes) [42,43]. Moreover,
whereas epithelial tight junctions, including choroid plexus epithelial
cells, mostly contain claudin-1, -2 and -11 [44], brain endothelial TJs
express claudin-3 and -5 and possibly claudin-12 [45,46]. In particular,
claudin-5 was shown to actively contribute to BBB integrity, inasmuch
as claudin-5 knock-out mice display severe BBB dysfunction and
permeability increase [47]. Accumulating further evidence indicates
that claudin-3 and -5 are involved, together with occludin, in BBB
genesis [46,48] and control of paracellular permeability [49–52].
The regulation of TJs appears to be mediated by multiple signaling
pathways (for review: [2]). Early in vitro experiments pointed to cAMP
as a major regulator of TJs in brain ECs [53]. Several evidences suggest
that phosphorylation and/or degradation of occludin and ZO-1
regulates TJs [54]. Later, serine/threonine phosphorylation of occludin
was associated to a decrease in paracellular permeability, whereas
tyrosine phosphorylation of ZO-1 was associated to an increase in
paracellular permeability [55,56]; also, VEGF was shown to affect TJ
assembly and increase BBB permeability by promoting occludin
phosphorylation [57] and/or degradation [58,59]. In addition, TJs are
regulated by the activation of small G proteins of the Rho family (Rho
GTPases) coupled to various receptors of vasoactive compounds
(Bradykinin, angiotensin II) as well as adhesion molecules (ICAM-1)
or reactive oxygen species: activation of Rho GTPases leads to actin
cytoskeleton rearrangements and increases paracellular permeability
as well as trans-endothelial migration of leukocytes [37,60,61].
Interestingly, crosstalk between components of TJs and Adherens
junctions was proposed to contribute to TJ regulation: ﬁrst, extra-
cellular calcium, known to control Adherens junctions integrity
via cadherins was also shown to regulate TJs. More recently, the
functional relationship between AJs and TJs was further documented
by the demonstration that VE-cadherin at AJs upregulates the
expression of claudin-5 at TJs, through activation of the transcription
factor Fox01 [62].2.3. Physiological function of the BBB
As mentioned above, the BBB is responsible for strictly controlling
the exchanges between the blood and brain compartments, by (i)
preventing the paracellular diffusion of hydrophilic solutes, (ii)
mediating the active transport of nutrients to the brain, (iii) efﬂuxing
hydrophobic molecules and drugs from the brain to the blood and (iv)
regulating the trans-endothelial migration of circulating blood cells
and pathogens.
2.3.1. Solute permeability
Because of the presence of TJs, BBB permeability to blood borne
solutes [63] largely depends on their molecular weight and lipophilic/
hydrophilic characteristics. A number of algorithms are available,
which help anticipate the BBB permeability of drug candidates on the
basis of their structural features [64,65], but they remain insufﬁciently
predictive [66]. Hydrophilic nutrients, such as amino acids, are
actively transported through the brain endothelium by a variety of
membrane transporters, notably the large family of Solute Carrier
transporters (SLC) [67]. In addition, although most proteins are not
able to diffuse across TJs, some of them efﬁciently cross the BBB by
receptor-mediated transport, as described for transferrin, insulin,
insulin-like growth factor, leptin or LDLs [68–70].
Conversely, efﬂux transporters of the ATP Binding Cassette (ABC)
family transport a large panel of lipophilic molecules, in particular
xenobiotics, against a concentration gradient by ATP hydrolysis
[63,71]. The most active ABC-transporters at the BBB are P-
glycoprotein (P-gp) encoded by the multidrug resistance gene
(MDR1 or ABCB1), multidrug resistance proteins (MRPs, or ABCC
proteins) and the breast cancer resistance protein (BCRP or ABCG2)
[72,73].
2.3.2. Trans-endothelial migration of circulating leukocytes
Leukocyte trans-endothelial migration, known as extravasation or
diapedesis, involves a complex set of adhesion molecules at the
surface of leukocytes and vascular endothelial cells [74] (Fig. 4).
Fig. 4. Trans-endothelial migration through the blood-brain-barrier. Leukocyte trans-endothelial migration proceeds in several steps that are highly controlled by various adhesion
molecules (selectins, LFA-1, VLA-4, CD44) and their respective counter-receptors (selectin ligands, ICAM-1, VCAM-1, CD44) expressed by ECs. After tethering and rolling, ﬁrm
adhesion and trans-endothelial migration of leukocytes are mediated by the formation of apical membrane protrusions, termed transmigratory cups, at the surface of ECs. Whether
these structures support paracellular (1) and/or trans-cellular (2) migration in vivo is still debated.
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endothelium which precedes diapedesis. Although tethering is
generally mediated by selectins, it appears in brain to be mostly
mediated by the integrins VLA-4 (α4β1) and α4β7 [34]. The
endothelial adhesion molecules ICAM-1, VCAM-1 and PECAM-1,
belonging to the superfamily of immunoglobulins, actively contribute
to the ﬁrm adhesion and/ormigration of distinct subsets of leukocytes
to the CNS through cytokine-activated brain endothelium [75,76].
Also, CD44, a polymorphic family of related membrane proteoglycans
was shown to play a pivotal role in lymphocyte trafﬁcking [77,78].
Recently, it has been shown that leukocytes were able to induce the
formation of endothelial membrane protrusions, containing ICAM-1,
VCAM-1 and CD44, linked to the actin cytoskeleton: because these
structures appear to support leukocyte trans-endothelial migration,
they are known as ‘transmigratory cups’ [79]. After migrating across
TJs, in the classical paracellular pathway, leukocytes interact with
CD99 and PECAM-1, present in the intercellular endothelial cleft,
between TJs and the endothelial basal lamina. In inﬂammatory
conditions, JAM-A is redistributed from intercellular junctions to the
endothelial apical membrane where they bind the leukocyte integrin
LFA-1 (αLβ2) [80,81], thus possibly contributing to leukocyte
diapedesis and migration to the brain [82,83]. More recently, the
prion protein PrPC was unexpectedly identiﬁed as an additional
junctional adhesion molecule involved in the trans-endothelial
migration of monocytes [84].
In addition to the migration of leukocytes across cell-cell junctions
(i.e. paracellular migration), the existence of a transcellular migration
pathway has recently been highlighted [85–87] (for review see
[86,88]). The previously described transmigratory cups are associated
to both paracellular and transcellular migration [86]. These structures
are in close contact with ICAM-1, caveolin-1 and the vesiculo-vacuolar
organ [89]. More recently, some other structures has been described
as actin-rich podosome-like membrane protrusions of leukocytes,
able to extend transiently through EC and these could be associated to
crawling and/or trans-endothelial migration of leukocytes [85,86].
Even if transcellular trans-endothelial migration has been proven in
brain EC [90], the relative importance of paracellular versus
transcellular endothelial migration in brain EC is still matter of debate
[86,89].
Because immunosurveillance exists in the CNS under physiological
conditions with inﬁltration of activated leukocytes (essentially T
lymphocytes and monocytes) across the cerebral endothelium, the
former conception that the CNS was an immune privileged site has
been recently tempered [91]. This has been recently dramaticallyhighlighted by the occurrence of severe JC virus infection in multiple
sclerosis patients treated with anti-VLA-4 monoclonal antibody
natalizumab inwhom leukocyte patrolling is presumed to be impaired
(see below) [92,93].
3. Blood-brain barrier in diseases
In a variety of neurological (inﬂammatory, infectious, neoplasic
and neurodegenerative) diseases, BBB dysfunctions have been
described, not only as a late event, but more interestingly as putatively
involved in the early steps of disease progression. Two related but
distinct types of BBB dysfunction will be documented below: (1)
increased permeability, i.e. passive diffusion of blood-borne sub-
stances through BBB TJs, associated with edema formation and (2)
massive cellular inﬁltration across the BBB.
3.1. BBB dysfunction in multiple sclerosis
Multiple sclerosis (MS) is a neuro-inﬂammatory, slowly progres-
sing and invalidating disease affecting 0.05%–0.15% of Caucasians
[94], mostly young adults, hence with a considerable social and
economic impact [95]. A key factor in MS progression appears to be
BBB alteration in genetically predisposed individuals, leading to
increased vascular permeability and leukocyte inﬁltration into the
brain [96,97].
3.1.1. Alteration of solute permeability in MS
Various animal studies on experimental autoimmune encephalo-
myelitis (EAE), the most commonly used MS animal model, suggest
that disease severity could be correlated with alteration of BBB
integrity, whereas limitation of the disease could be achieved by
preventing BBB alterations (Fig. 5) [98–100]. At the molecular level,
occludin dephosphorylation was shown to be timely associated with
the onset of clinical signs [100] and was indeed recently suggested to
mediate the permeability increase in response to angiotensin II, acting
via its ATI receptor expressed by brain endothelial cells [16].
Additional observations on brain tissue from MS patients further
pointed to a correlation between BBB permeability increase and loss
or delocalization of brain endothelial junction proteins, like occludin,
VE-cadherin or ZO-1 [101,102]. However, interpretation of these data
(primary lesions, secondary damage or reparation default) remains a
matter of debate [101]. Such an increase in BBB permeability in active
MS lesions, commonly referred to as ‘BBB opening’, is visualized using
magnetic resonance imaging (MRI) by monitoring the diffusion of
Fig. 5. Blood-brain-barrier alterations in multiple sclerosis. Accumulating data suggest the contribution of BBB dysfunction in the onset and progression of multiple sclerosis (MS).
Several mechanisms account for alteration of TJ integrity (1): decreased expression of occludin and ZO-1 and changes in occludin phosphorylation status. In addition, activatedMMPs
directly contribute to alteration of basal lamina (2). Finally, up-regulation of the expression of several adhesion molecules by brain ECs supports the increased trans-endothelial
migration of leukocytes (3) observed in MS.
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endothelial TJs [103].
BBB permeability has been well documented to be increased by
MMPs, in line with early reports showing that intracerebral injection
of MMPs increased brain capillary permeability [104]. More recently,
various data in animal and clinical studies further highlighted the role
of MMPs in the pathophysiology of MS [12,105]. In particular, the
serum MMP9 level in MS patients was correlated with the BBB
dysfunction index, as measured byMRI using gadolinium as a contrast
agent [103,106].
3.1.2. Increased trans-endothelial migration of leukocytes in MS
Although the etiology of the disease still remains elusive, it was
hypothesized that systemic infection or inﬂammation might enhance
the expression of adhesion molecules on brain ECs, allowing activated
lymphocytes and monocytes to access the CNS (Fig. 5) [95]. Indeed,
overexpression of leukocyte adhesion molecules by brain ECs (ICAM-
1, VCAM-1, E-selectin) has been extensively documented in brain
lesions of MS patients, compared with normal appearingwhite matter
or control tissue [107–109]. Accordingly, it was established that IFN-β,
a current treatment in MS known to delay inﬂammation-associated
disease relapses, could prevent the increase in ICAM-1 expression by
brain ECs in response to the inﬂammatory cytokine TNF-α [110] and
decrease VLA-4 expression by lymphocytes [111,112]. Moreover,
whereas early reports indicated that anti-VLA-4 antibodies could
delay or prevent the onset of EAE in rodents [77,113], a similar
approach (using the anti-VLA-4 monoclonal antibody natalizumab)
was shown to signiﬁcantly decrease the number of relapses in MS
patients [92,93] and has now been approved for clinical use.
Interestingly, antibodies against the recently identiﬁed adhesion
molecule ALCAM (activated leukocyte cell adhesion molecule), the
expression of which by brain endothelium is up-regulated in MS
lesions, were similarly shown to improve the functional outcome of
EAE in rodents, indicating that ALCAM, together with ICAM-1 and
VCAM-1, are involved in leukocyte trafﬁcking into the CNS in
inﬂammatory conditions [114].It must be stressed that BBB permeability increase and leukocyte
inﬁltration in the brain are two related, although distinct, conse-
quences of CNS inﬂammation. Indeed, whereas CD4+ IL-17-produ-
cing T lymphocytes (Th17) were recently identiﬁed as major actors in
disease progression, at least part of their pathological role may be
mediated by IL-17 which is able to disrupt brain endothelium TJs [115–
117]. In addition, circulating monocytes have been shown, after
crossing the BBB, to acquire dendritic cell function and further
enhance the inﬁltration of Th17 lymphocytes by releasing chemokines
across the BBB [116,118]. Whereas gadolinium-enhanced MRI allows
imaging of increased BBB permeability, recent MRI developments
(using ultra small particles of iron oxide, so-called USPIO) aim at
tracking inﬁltrated monocytes/macrophages and may thus provide a
valuable complementary imaging strategy in MS [119,120].
3.2. BBB dysfunction in stroke
Acute obstruction of cerebral blood vessel by clot formation
triggers a complex series of cellular and molecular events in the
brain parenchyma (membrane depolarization of neurons and astro-
cytes, release of excitatory amino acids and K+ ions in interstitial
ﬂuids, increase of intracellular Ca2+ levels), ultimately leading to
dramatic cell damage within hours [121]. While administration of
neuroprotective agents has generally failed as a potential treatment,
thrombolysis by tissue plasminogen activator (tPA) within hours after
the onset of the symptoms so far remains the only efﬁcient therapy in
stroke [122]. However, it soon appeared that the ischemia/reperfusion
sequence of events initiates perivascular inﬂammation and BBB
permeability increase which largely contribute to brain damage,
thus leading to the concept that stroke is primarily a cerebrovascular
disorder [123].
3.2.1. Altered BBB permeability in stroke
Early reports already pointed to rapid alterations of brain
endothelium after cerebral ischemia and reperfusion, an early phase
occurring minutes after reperfusion, followed by a second phase
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lytic enzymes and inﬂammatory cytokines were shown to alter the
BBB permeability properties, leading to brain edema formation [121].
Accordingly, MMPs released by activated leukocytes affect the
integrity of the NVU, degrading the basal lamina and TJ-associated
protein complexes (Fig. 6) [12,127–129]. In particular, MMP9 seems to
play a critical role, as suggested by the absence of BBB disruption after
transient ischemia in MMP9 gene deﬁcient mice and the demonstra-
tion of its contribution to hemorrhages after stroke and thrombolysis
by t-PA treatment [127,130]. Whereas tPA permeability across the BBB
is physiologically controlled by an LDL receptor-dependent mechan-
ism, BBB breakdown after stroke will lead to passive diffusion of tPA
into the brain which may account for its reported neurotoxic side
effects [131]. New thrombolytic agents, with no apparent neurotoxic
effect, may be useful for designing alternative therapeutic strategies
[132].
In conclusion, the complex cellular and molecular changes leading
to BBB breakdown after an ischemia/reperfusion event remain to be
further understood, before novel treatments of brain edema and
stroke prevention can be proposed.
3.2.2. Increased trans-endothelial migration of leukocytes in stroke
Some recent data suggest that leukocyte inﬁltration into the brain
parenchymamight contribute to cerebral ischemia/reperfusion injury
[133,134]. Following stroke, circulating activated leukocytes will
migrate towards the ischemic lesion, release inﬂammatory cytokines
and activate the various NVU cell types [135]. In particular, increased
expression of ICAM-1 by brain ECs facilitate the trans-endothelial
migration of leukocytes [136,137], in line with the experimental
evidence that treatment with anti-ICAM-1 blocking antibodies
reduced brain injury in a rat model of cerebral ischemia [138]. Also,
transgenic mice deﬁcient in ICAM-1 or in its integrin receptor LFA-1
failed to present cerebral inﬁltration of leukocytes following cerebral
ischemia as compared with wild-type animals and had a signiﬁcantly
better functional outcome [139]. Based on these preclinical encoura-
ging data, a randomized, double-blind, placebo-controlled, clinical
trial using injection of a monoclonal anti-ICAM-1 antibody was
performed, but failed for reasons which remain to be clariﬁed
[140,141].
3.3. BBB dysfunction in brain tumors
Neovascularisation in primary brain tumors is correlated with
tumor progression and morbidity phenotypes [142]. Angiogenesis-
related BBB alterations have been well documented both in terms ofFig. 6. Blood-brain-barrier alteration in stroke. Within hours following clot formation in br
inhibitors in favor of MMPs, leading to alteration of the basal lamina (1) and TJs (3). Brain E
adjacent endothelial cells.structural changes of the cerebral vasculature and related perme-
ability increase. In addition, it was recently emphasized that brain ECs
may closely interact with brain tumor stem cells such as gliobastoma
stem cells [143] and maintain their stemness [144].
3.3.1. Increased BBB permeability in brain tumors
Newly formed blood vessels in primary brain tumors were shown
to present an abnormal overall structure, being more tortuous than
normal brain vessels, lined with an altered basal lamina [145]. In
addition, loss of expression of the TJ proteins claudin-3 and occludin
were reported in primary experimental and human brain tumors
[145,146]. Recent data showed that VEGF, an angiogenic growth factor
known to be produced at a high level in brain tumors [147,148],
promoted endocytosis of the endothelial cell adhesion molecule VE-
cadherin, leading to disruption of the endothelial barrier function and
increase in endothelial permeability [149].
Moreover, the level of occludin expression was proposed to be
inversely correlated with brain tumor grading and with the degree of
enhancement in CT scans, corresponding to the blood-to-brain
diffusion of contrast products [146]. All together, these observations
provide compelling evidence that primary brain tumor-associated
angiogenesis induces structural and functional alterations of the BBB.
3.3.2. Increased trans-endothelial migration of metastatic tumor cells
in the brain
Cells originating from peripheral primary tumors, such as breast
cancer or melanoma, can circulate in the blood ﬂow to the brain and
form cerebral metastases, invariably associated with bad prognosis.
Studies on the mechanisms involved in the trans-endothelial migra-
tion of these metastatic cells across the BBB further highlighted the
crucial contribution of VEGF, which is highly expressed by breast
carcinoma cells [150], and MMPs [151].
In addition, the leukocyte adhesion molecule CD44 was shown to
contribute to the adhesion of metastatic breast carcinoma cells to
brain vascular endothelium. Regarding the mechanisms of their
subsequent trans-endothelial migration, data suggest a major role of
the chemokine CXCL12 (or SDF-1α) expressed in the brain and its
counter-receptor CXCR4 present at the surface of metastatic tumor
cells [152,153]. Indeed, blocking the CXCR4-dependent intracellular
pathways (PI3Kinase activation, intracellular Ca2+ increase) pre-
vented the trans-endothelial migration of a breast cancer metastatic
cell line through cultured human brain ECs [152]. Moreover,
preliminary results indicated that adhesion of breast carcinoma
cells on cultured brain ECs induced the formation of actin-rich apical
membrane protrusions (unpublished observations), similar to theain microvessels, oxygen deprivation leads to an imbalance between MMPs and their
Cs release large amounts of reactive radicals, NO and O2− (2), which diffuse and affect
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leukocyte diapedesis [154]. In the same line, small-cell lung cancer
cells were reported to cross brain endothelium by inducing a
reorganization of the endothelial actin cytoskeleton through activa-
tion of Rho GTPase [155]. In conclusion, some metastatic tumor cells
appear to share with activated leukocytes the expression of multiple
adhesion molecules and chemokine receptors which provide them
with the capacity to adhere to brain endothelium, to activate it and
ﬁnally to cross the BBB. Following trans-endothelial migration, these
tumor cells will receive multiple local inputs which will sustain their
survival, migration and proliferation towards the formation of brain
metastases [156].
3.4. CNS infection
3.4.1. Bacterial meningitis
Because of the existence and function of the BBB, most blood-
borne pathogens are excluded from the brain. Only a few bacteria are
able to enter the brain and evoke inﬂammation and disease. Among
them, Neisseiria meningitidis (also known as meningococcus), Strep-
tococcus pneumoniae and Haemophilus inﬂuenzae which multiply
extracellularly, as well as Group B Streptococcus and Escherichia coli K1
in newborn, and Listeria monocytogenes which multiplies within
macrophages can invade the meninges, causing meningitis, or the
cerebrospinal ﬂuid (CSF) after entering the bloodstream.
3.4.1.1. Increased BBB permeability by bacterial secretions. Whereas L.
monocytogenes and other intracellular pathogens appear to cross the
BBB within leukocytes as ‘Trojan horses’, the extracellular pathogens
mentioned above have developed individual strategies which allow
them to adhere to and cross brain endothelium, thus exhibiting brain
tropism (Fig. 7). These bacteria induce, by releasing lipopolysacchar-
ide (LPS) and/or toxins, the secretion of multiple cytokines and otherFig. 7. Pathogens crossing the blood-brain-barrier. Circulating bacteria release active factor
cytokines (TNFα, IL1β, PAF, TGFβ1) and MMPs which in turn alter both brain endothelial TJs
various membrane proteins expressed by cerebral ECs as receptors to cross the BBB by transc
by the external membrane proteins OmpA and FimH with their respective receptors gp
Streptococcus pneumoniae interacts by the cholin binding protein A to PAF on ECs. In additi
PAF, MMPs, TGFβ1, caspases) which are able to increase trans-endothelial migration, S. pneu
and LPS inducing EC apoptosis. Neisseiria meningitidis (also known as meningococcus) intera
adhered on EC, they are able to induce the formation of actin-rich membrane processes
endothelial migration.inﬂammatory components (TNF-α, IL1β, PAF, MMPs, TGFβ1, caspases)
which are all able to increase microvascular permeability, including in
the brain [157]. Indeed, the CSF level of some of them (TNFα, IL1β,
TGFβ1) in childrenwas correlated with the clinical outcome [158,159],
whereas the CSF level of MMP9 was correlated with neurological
impairment [160,161]. These inﬂammatory cytokines are known to
increase the trans-endothelial migration of leukocytes which, when
inﬁltrated in the brain compartment, can locally release cytokines and
MMPs, thus amplifying the activation of brain endothelium and the
inﬂammation within the CNS [162]. In addition, direct lesion of brain
ECsmay affect BBB integrity and facilitate brain infection as in the case
of S. pneumoniae which secretes pneumolysin, a hemolysin forming
transmembrane pores in brain ECs [163], and LPS inducing EC
apoptosis [164].
3.4.1.2. Trans-endothelial bacterial entry in the brain. Recent experi-
mental data led to a better understanding of the mechanisms
mediating the trans-endothelial migration of E. coli K1, N. meningitidis
and S. pneumoniae across the BBB [165,166]. These bacteria display
individual attributes which allow them to adhere to brain endothe-
lium by interactions with endothelial receptors, as shown in Fig. 7. In
the case of N. meningitidis, bacterial adhesion to ECs is mediated by
elongated multimeric structures known as type IV pili. The formation
of actin-rich membrane processes involved in bacteria internalization
is highly reminiscent of the leukocyte trans-migratory cups; more-
over, the signaling pathways activated in ECs in response to the
adhesion of N. meningitidis are similar to those induced by activated
leukocytes, indicating that bacteria may interfere with leukocyte–EC
interaction and hamper host inﬂammatory response [166,167].
3.4.2. Viral infection of the CNS
Infection by HIV and other neurotropic viruses such as West-Nile
or Chikungunia virus highlighted the pathophysiological importances (LPS, toxins, etc.) inducing the local production by the host of various inﬂammatory
and the basal lamina and ultimately increase BBB permeability. In addition, bacteria use
ytosis. Escherichia coli K1 strain mainly responsible for meningitis in newborn interacts
96 and CD48 on brain ECs. This interaction triggers transcytosis through brain ECs.
on to secreting multiple cytokines and other inﬂammatory components (TNF-α, IL1β,
moniae secretes pneumolysin, a hemolysin forming transmembrane pores in brain ECs
cts by his type IV pili with a yet not identiﬁed brain endothelial receptor. Once they have
highly reminiscent of the leukocyte trans-migratory cups which support their trans-
Fig. 8. The blood-brain-barrier in Alzheimer disease. In healthy condition (right), Aβ
amyloid peptide is transported to brain by the receptor for advanced glycosylation
products (RAGE) and cleared from the brain to the blood by LDL-Receptor-Proteins
(LRPs). In Alzheimer's disease (left), these transport systems are impaired. RAGE is
overexpressed and the expression of LRPs is decreased, leading to the accumulation of
Aβ in the brain.
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as an obstacle for pharmacological treatment.
3.4.2.1. Altered BBB permeability in viral CNS infection. Various
immunohistological studies of post-mortem brain tissue from patients
with HIV encephalitis revealed a reduced expression of claudin-5 and
occludin by brain endothelium [168]; accordingly, in vitro interaction
of HIV-infected human lymphocytes with primary human brain ECs
also induced a loss of these TJ proteins [168]. In the same line, a recent
report demonstrated that HTLV-I-infected lymphocytes increased
brain endothelial permeability in vitro via IL-1α and TNF-α secretion
and that BBB breakdown was associated with endothelial TJ
disorganization and alteration in the expression pattern of TJ proteins
such as ZO-1 [36].
3.4.2.2. Trans-endothelial migration of virus-infected leukocytes. Some
neurotropic viruses can cross brain endothelium by transcytosis, i.e.
HIV, HTLV-1 or cytomegalovirus (CMV) [169,170], likely after macro-
pinocytosis of free viral particles.
In addition, trans-endothelial migration of infected leukocytes
constitutes an alternative route for entry into the CNS [171,172].
Infectionwas shown to increase the expression of adhesion molecules
(integrins and selectins), in infected monocytes, lymphocytes and
macrophages, favoring paracellular trans-endothelial migration of
infected cells [170,173,174]. Moreover, this process is dependent upon
several chemokines expressed in the brain in response to HIV
infection and in inﬂammatory conditions, like CXCL12 (SDF-1α),
CCL2 (MCP-1) and CX3CL1 (fractalkine): indeed, elevated levels of
CXCL12 were detected in CSF and in brain tissue of HIV-infected
patients [175,176], whereas high levels of the receptors of CXCL12 and
CX3CL1 (CXCR4 and CX3CR1, respectively) were observed in HIV-
infected monocytes [177,178]. Finally, HIV- and HTLV-I-infected cells
were shown to produce high levels of MMPs which likely affect basal
lamina integrity at the BBB and contribute to enhance their trans-
endothelial migration to the brain [179,180].
3.5. Neurodegenerative diseases and BBB dysfunction
Age-related neurodegenerative diseases, such as Parkinson's and
Alzheimer's disease (AD), constitute a major public health problem in
western countries. Although BBB has long been dismissed in this type
of CNS disease, recent data strongly suggested that BBB dysfunction
might contribute to disease progression [181–183].
3.5.1. Altered BBB permeability in neurodegenerative diseases
Early observations of post-mortem brain tissue from AD patients
pointed to a number of brain endothelium alterations: decreased
number of mitochondria, increased number of pinocytosis vesicles,
collagen accumulation in basal lamina and necrosis [184]. More
recently, various clinical investigations of AD patients using gadoli-
nium-enhanced MRI or biochemical methods, such as assessment of
the CSF/blood albumin ratio, detected functional alterations of the BBB
bymeasuring permeability increase compared to age-matched controls
[185]. More recently, identiﬁcation and functional characterization of
peptides andproteins transport through the BBB [186–188], brought up
a comprehensive view of the transport of Aβ through cerebral
endothelium. Aβ peptide inﬂux into the brain is mediated by the
receptor for advanced glycosylation products (RAGE) [189] and is
dependent on Aβ chaperones, apoE and apoJ [190]: apoE2 and apoE3,
but not ApoE4, block the transport of Aβ to the brain [191]. The
clearance of Aβ out of the brain is mediated by the lipoprotein receptor
protein (LRP)-1 [192]. This transport activity of Aβ is altered in AD
patients (Fig. 8). Indeed, the AD characteristic Aβ amyloid peptide
deposits observed in senile plaques and perivascular spaces were
suggested as a consequence of age-dependent decrease of Aβ
clearance (due to lower expression of LRP-1) and increase in Aβinﬂux to the brain (due to increased expression of RAGE [189,193–
195]). In addition, soluble forms of LRP-1 that normally sequester
blood Aβ peptide and reduce its inﬂux into the brain are detected in
lower amounts, which may contribute to further increase brain Aβ
levels [196]. The role of LRP-2 in Aβ efﬂux and in AD is still debated
[196]. Altogether these observations strongly suggest that age-
dependent alteration of Aβ transport across the BBB may signiﬁcantly
contribute to AD progression.
In the same line, increased BBB permeability associated with a loss
of TJ integrity was also demonstrated in animal models of temporal
epilepsy or status epilepticus [197].
3.5.2. Increased trans-endothelial migration in Alzheimer's disease
Increased expression of ICAM-1 in senile plaques was reported in
human and primate brain tissues, suggesting an inﬂammatory
component in their formation and involvement in AD progression
[198,199]. In addition, cerebral inﬁltration of T lymphocytes has been
recently described in AD patients, in line with previous reports in
Parkinson's disease [199–203]. Furthermore, Aβ is able to induce
monocytes inﬁltration through the BBB by a mechanism that
implicates RAGE and PECAM-1 [204].
In conclusion, accumulating experimental as well as clinical
evidence support the concept that BBB dysfunctions signiﬁcantly
contribute to the progression of a number of inﬂammatory, infectious
or neoplasic diseases of the CNS. Furthermore, additional data, based
on a better understanding of the molecular mechanisms of BBB
function, point to a putative and so far unsuspected role of the BBB in
the initiation of various neurodegenerative diseases, in particular
following age-dependent alterations of its transport properties, as
suggested in AD patients. Besides, even when altered in these
situations, the BBB has long been considered as a major obstacle for
drug delivery to the CNS. Although still not resolved so far, this key
question has been addressed by various strategies which will be
brieﬂy considered below.
4. Therapeutic approaches
Because of the existence of the BBB, the ﬁrst approach ever used to
target drugs to the CNS was to try to circumvent it by direct intra-CSF
or intra-cerebroventricular injections, in particular to target che-
motherapy to some brain tumors. However, drug diffusion from the
CSF to the brain parenchyma being usually poorly efﬁcient [205],
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implanted catheters, or by post-surgery implantation of drug-
impregnated wafers within the resection cavity, have been used as
alternative strategies to treat patients with aggressive gliomas [206].
More recently, progresses in the understanding of the speciﬁc
structural and functional characteristics of the BBB have helped design
alternative therapeutic approaches for drug targeting to the brain by
(i) increasing BBB permeability, (ii) modulating transporter expres-
sion and/or activity, (iii) taking advantage of receptor-mediated
transport across the BBB, (iv) designing viral, chemical and cellular
vectors with the capacity to cross the BBB (Fig. 9).
4.1. Increase BBB permeability
Local drug administration via intracerebral implants offers only
little beneﬁt to patients with brain tumors due to limited diffusion of
the drug in brain tissue [207]. Hence, temporary disruption of the BBB
was considered and achieved by intracarotid infusions of hyperosmo-
tic solutions of chemical agents, mannitol or alkyl glycerol [208].
Among them, mannitol has been the most widely investigated [209]:
mannitol causes reversible shrinkage of brain ECs by water efﬂux,
leading to TJ disruption and increased drug diffusion to the brain. This
strategy was proposed for enhanced delivery of anti-cancer drugs,
viral vectors or nanoparticles [102,209,210]. However, the risk of toxic
side effects may limit this strategy to highly aggressive and life-
threatening diseases.
Transient BBB opening could also be performed by using
ultrasound with or without contrast products, e.g. microbubbles
[211,212]. This alternative strategy may limit neuronal damage by
targeting a restricted brain area for BBB opening and drug delivery,
even if the molecular mechanisms of permeability changes remain
largely unknown [211–216]. Interestingly, this new approach was
recently proposed for thrombolysis after acute ischemic stroke [213]
andmight be of interest for delivery of a plethora of substances such as
immunoglobulins, viral vectors, plasmid DNA, siRNA, mRNA or high
molecular weight drugs [217].
Besides, pharmacological approaches to increase BBB permeability
are based on our knowledge that vasoactive mediators affect
endothelial permeability by binding to apical membrane receptorsFig. 9.Drug targeting across the blood-brain-barrier. The BBB is a major obstacle for drug deliv
limitations: the route of delivery is showed at the top whereas examples of strategies are inand triggering intracellular signal transduction leading to changes in
junctional complexes [218]. Indeed, bradykinin being known to
increase the permeability of intra-tumoral blood microvessels, RMP-
7, a bradykinin analog, was tentatively used to increase drug delivery
to brain tumors; however a randomized, double-blind, placebo-
controlled, phase II clinical study in recurrent malignant glioma failed
to conﬁrm previous preclinical data [219].
4.2. Modulate efﬂux transport activity at the BBB
It has been mentioned above that the BBB permeability properties
are not only dependent upon the presence of endothelial TJs, but also
upon the polarized expression of a number of ABC-transporters which
protect the brain by efﬂuxing into the blood a wide variety of
hydrophobic, potentially neurotoxic compounds. These transporters
are also responsible for poor delivery and poor overall efﬁcacy of a
number of active drugs, including anti-cancer and anti-viral drugs. It is
worth mentioning that the anti-viral drugs successfully used in anti-
HIV therapy (abacavir, zidovudine, efavirenz, tenofovir, emtricitabine)
are ABC-transporter substrates, which cannot efﬁciently get access to
virus-infected brain cells, leading to the concept of CNS as a viral
reservoir for HIV. As a consequence, blocking ABC-transporter activity
at the BBB was proposed as a strategy to increase cerebral delivery of
anti-HIV drugs [71,220,221]. Experimental evidence strongly supports
this hypothesis, by demonstrating that intracerebral concentrations of
several HIV protease inhibitors are largely increased in brains of P-gp
knock-out mice compared with wild-type animals, or after adminis-
tration of P-gp blockers in wild type mice [222,223].
4.3. Control receptor-mediated transport through the BBB
Multiple active transport systems are present at the BBB, which
control nutrient access to the CNS across the BBB [205]. Taking
advantage of these various receptor-mediated transport systems
expressed at the luminal side of brain ECs has long been a tempting
approach to deliver drugs to the brain compartment. Themost studied
and best characterized receptors in this ﬁeld are the transferrin and
insulin receptors [224,225] which are known to be internalized after
ligand binding and to mediate transcytosis of their ligand to theery to the brain. Several approaches are currently proposed in order to circumvent these
dicated at the bottom (for further details and abbreviations, see the text).
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feasibility of such approaches have been provided by various
investigators for more than two decades, using drugs of interest
covalently linked to these ligands or to ligand-mimicking anti-
receptor antibodies, or incorporated in targeted liposomes or
nanoparticles [68,226–229]. However, it must be emphasized that,
to our knowledge, no successful clinical trials have been reported yet,
suggesting that the drug delivery efﬁcacy attainable by this strategy
remains very low at the present time. More recently, similar strategies
have been proposed using the LRP-1/LRP-2 receptors or the diphteria
toxin receptor [230] and validation of these alternative approaches is
in progress. Conversely, it is worth mentioning that inhibition of
RAGE, which as mentioned above, mediate Aβ peptide inﬂux into
the brain, is currently tested as a potential therapeutic strategy in
AD [231].
4.4. Cellular vectors
Based on our current knowledge of the mechanisms of leukocyte
migration across the BBB, several studies were recently focused on the
capacity of bone-marrow-derived cells or neural precursor cells
(NPCs) to migrate across brain ECs. It has been shown in rodents
that genetically engineered bone-marrow-derived cells were able to
cross the BBB, which might be of great interest for the cerebral
delivery of genes, enzymes, growth factors in neurological diseases
[232]. It must be stressed however that, although strategies of
allogenic bone marrow cell transplantation have been proposed in
MS, their efﬁciency is still debated [233,234].
Neural precursor cells, when injected intravenously in several
animal models of neurological diseases (MS, Parkinson's or neurode-
generative metabolic diseases), were recently documented to cross
the BBB and to signiﬁcantly improve the outcome of the correspond-
ing disease [235–242]. Recent evidence suggests that these cells may
mimic leukocytes in interacting with brain microvascular ECs and
cross the BBB using an active mechanism [243]. Although technical or
ethical concerns have to be considered, it is then tempting to speculate
that systemic delivery of neural precursor cells might constitute a
clinical alternative in the future.
5. Conclusion
The BBB is present at the interface between the brain and the
periphery. It strictly controls the exchanges between both compart-
ments, by actively transporting nutrients to the brain and protecting
the CNS from various xenobiotics and pathogens. Its extremely low
permeability is due to inter-endothelial TJs and the activity of multiple
efﬂux transport systems. In addition, migration of circulating cells,
notably activated leukocytes, across the BBB is a ﬁnely regulated
dynamic process, responsible for the low-level but signiﬁcant
immunological survey of the brain in physiological conditions.
BBB dysfunction, often referred to as “BBB opening”, has long been
known to constitute a key feature of the progression of several CNS
diseases, as a consequence of neuro-inﬂammation. A closer observa-
tion of these pathological situations, based on a better knowledge of
the biology of the BBB, led to the understanding that increased BBB
permeability, clinically detected by gadolinium diffusion in MRI
analysis, may or may not be accompanied by increased leukocyte
migration across the BBB, these two events being clearly distinct on a
molecular basis. In addition, experimental data strongly suggest that
impaired clearance of the amyloid Aβ peptide across the BBB might
largely contribute to the formation of Aβ brain deposits and AD
progression, thus suggesting a causative role of BBB dysfunction in a
neurodegenerative disease.
It is likely that the recent progresses in our current knowledge of
TJ regulation, transport activity and leukocyte transmigration at the
BBB will pave the way to novel therapeutic strategies for CNSdiseases. Just like anti-VLA-4 antibody treatment has recently
appeared as a beneﬁcial approach to limit leukocyte inﬁltration to
the brain in MS, the identiﬁcation of various active transport systems
or other membrane proteins at the BBB may allow for the
development of new brain-targeted strategies to efﬁciently deliver
drug to the CNS. Finally, systemic delivery of hematopoietic stem cells
or neural precursor cells, based on the ability of these cells to cross
the BBB, might constitute in the future alternative approaches for
drug delivery to the brain in the context of aggressive neurodegen-
erative diseases.
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